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Leishmania parasites cause human tegumentary and visceral infections that are commonly referred to as
leishmaniasis. Despite the high incidence and prevalence of cases, leishmaniasis has been a neglected disease
because it mainly affects developing countries. The data obtained from the analysis of patients’ biological samples
and from assays with animal models confirm the involvement of an array of the parasite’s components in its
survival inside the mammalian host. These components are classified as virulence factors. In this review, we focus
on studies that have explored the role of proteinases as virulence factors that promote parasite survival and
immune modulation in the mammalian host. Additionally, the direct involvement of proteinases from the host in
lesion evolution is analyzed. The gathered data shows that both parasite and host proteinases are involved in the
clinical manifestation of leishmaniasis. It is interesting to note that although the majority of the classes of
proteinases are present in Leishmania spp., only cysteine-proteinases, metalloproteinases and, to a lesser scale,
serine-proteinases have been adequately studied. Members from these classes have been implicated in tissue
invasion, survival in macrophages and immune modulation by parasites. This review reinforces the importance of
the parasite proteinases, which are interesting candidates for new chemo or immunotherapies, in the clinical
manifestations of leishmaniasis.
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Introduction
Leishmaniasis is a vector-borne infection that is present
in the Americas, Africa, eastern Europe, western and
central Asia, India and Australia [1,2]. The genus Leish-
mania includes protozoan parasites that cause several
types of human infections ranging from the visceral
form to the tegumentary forms (cutaneous, diffuse cuta-
neous, mucocutaneous and post-kalazar dermal). In
addition to humans, animals such as dogs, rodents and
marsupials are also susceptible to Leishmania infections
[3].
Currently, it is estimated that 1–1.5 million new cases
of tegumentary leishmaniasis and 0.5 million new cases
of the visceral form occur each year [4], and the number
of leishmaniasis cases occurring outside of the endemic* Correspondence: calves@ioc.fiocruz.br
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distribution, and reproduction in any mediumcountries has been increasing due to tourism, military
operations and the movement of immigrants from en-
demic countries [5]. There are two evident morpho-
logical phases in the life cycle of these protozoa: (1)
elongated promastigotes with visible flagella that inhabit
sandfly guts and (2) round-shaped amastigotes without
visible flagella that inhabit mammalian cells [6]. During
the natural infection, the metacyclic promastigotes are
carried by the blood-sucking sandflies that mediate the
transmission between mammalian hosts. It has been
reported that, in some human cases, the hosts may re-
main asymptomatic for a long time and thus play an im-
portant role in the vector-borne transmission of
leishmaniasis in their regions [7].
During the blood meal, the insect vector deposits
metacyclic promastigotes in the skin of its host. These
promastigotes are the virulent form of Leishmania and
initiate the infection. The first sign of infection is a small
erythema at the site of the sandfly bite that develops
after a variable incubation period. The erythemaentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gradually ulcerates over a period ranging from two
weeks to six months, eventually becoming the character-
istic lesion of localized cutaneous leishmaniasis, as
reviewed by [8]. Once in the skin, the parasites are
exposed to new microenvironments, such as the extra-
cellular matrix (ECM) of connective tissue, and must
interact with a variety of obstacles, including basement
membrane proteins, until establishing infection within
macrophage phagolysosomes [9,10].
Currently, it is known that the distinct clinical mani-
festations of leishmaniasis are dependent upon the para-
site species and the status of the host’s immune system
[10] and result from interactions between host immune
factors and parasite components. These manifestations
can be divided into three main profiles: (1) an anergic
pole, where ulceration is not observed even with a high
parasite number in the lesion, characterizes the diffuse
cutaneous form; (2) an equilibrated profile characterizes
the localized cutaneous form or benign disease, and (3) a
hypergenic pole that is observed in mucosal leishmania-
sis, in which few parasites are found in the lesions des-
pite the elevated cellular response of the host [11-14].
Some parasite components are characterized as viru-
lence factors that contribute to Leishmania pathogenesis
and enable the parasite to invade and establish infection
in the mammalian host [15]; these virulence factors in-
clude glicoinositolphospholipids (GIPLs), lipophospho-
glycan (LPG), proteophosphoglycan (PPG) and the
11 kDa kinetoplastid membrane protein (KMP-11). Al-
though the exact impact of these Leishmania compo-
nents on the clinical manifestations observed in
mammalian hosts is not yet defined, there is evidence
that these components modulate the interactions be-
tween Leishmania and host immune cells.
For example, GIPLs were reported to help Leishmania
(Leishmania) major survive inside macrophages by inhi-
biting nitric oxide synthase [16] and protein kinase C
[17]. Recently, a correlation was shown between the rate
of macrophage infection by Leishmania (Viannia) brazi-
liensis and the GILP-containing detergent-resistant
membrane domains of this parasite [18].
Lipophosphoglycan is a macrophage ligand that is
directly involved in the initial stages of the infection.
Assays carried out with a mutant strain of L. (L.) major
deficient in the gene lpg1 (lpg1-) showed that the mutant
parasites are attenuated for virulence during infections
of murine macrophages, despite presenting no major
phenotypical changes. These parasites lacked LPG but
contained normal levels of related glycoconjugates and
GPI-anchored proteins. The lpg1- promastigotes are
highly susceptible to the complement system and to the
oxidants produced by host cells. In addition, they lose
their ability to inhibit phagolysosome fusion. It has alsobeen reported that L. (L.) major LPG2 null mutants
(lpg2-) were unable to survive in sandflies or in mamma-
lian host cells. These parasites were more altered than
the lpg1- mutants and lacked all phosphoglycans, includ-
ing LPG and proteophosphoglycans [19-23]. Leishmania
LPG has been shown to impair the nuclear translocation
of NF-κB in monocytes, leading to a subsequent de-
crease in IL-12 production [24], and can also influence
the host’s early immune responses by modulating den-
dritic cells by inhibiting antigen presentation and pro-
moting an early IL-4 response [25].
Proteophosphoglycans are highly glycosylated polypep-
tides with O-glycosylations similar to those found in the
LPG and acid phosphatase [26,27]. The function of
membrane PPGs is not entirely clear, but it is speculated
that its long chain that covers the plasma membrane of
the parasite could play some role in binding to macro-
phage receptors. The secretion of modified PPG by para-
sites within macrophages appears to contribute to
maintenance of the parasitophorous vacuole [28]. Add-
itionally, the PPG is also able to activate complement via
mannose-binding protein [29].
KMP-11 is a hydrophobic protein that has been
described to be associated to LPG [30]. This protein has
presented immunoregulatory properties and is able to
induce the expression of IL-10 in cells from patients
with cutaneous and mucocutaneous leishmaniasis [31];
however, the mechanism through which this effect
occurs remains unclear.
Proteinases of Leishmania as virulence factors
Proteinases are also important virulence factor candi-
dates, as they are enzymes that hydrolyze peptide bonds
and thus have the potential to degrade proteins and
peptides that participate in a broad range of biological
functions, including the infection process (Table 1).
Proteinases occur ubiquitously in biological systems
and have functions that range from the digestion of
proteins for nutritive purposes to the exquisite control
of protein function by hydrolyzing a highly specific
peptide bond in a protein substrate [32].
They can be classified, based on their catalytic
domains, as serine-, threonine-, aspartyl-, metallo- and
cysteine-proteinases [63]. Among these, only the aspar-
tyl-, metallo- and cysteine-proteinase classes have been
extensively studied in Leishmania species [64-67].
There are several examples of parasite proteinases
being involved in pathogenesis and playing roles in para-
site invasion and migration through host tissues, degrad-
ation of immune related proteins, immune evasion and
activation of inflammation [68]. In protozoan parasites,
proteinases play key roles in the life cycle transitions,
invasion of hosts, migration through tissue barriers,
degradation of hemoglobin and other blood proteins,
Table 1 Immunological actions of proteinases on the mammalian immune system that drive clinical manifestations of
Leishmaniases
Proteinase classes Leishmania species Activities on mammalian host References
Cysteine proteinase CPA L. (L.) infantum Related to the ability to infect mammalian hosts cells in vitro; [33]
CPB L. (L.) mexicana Associated with a Th2 profile in BALB/c mice: inducing lesions; IL-4 and IL-5
production; inhibition of IL-12 production by cleaving NF-κB; inhibition of NO
production by cleaving the STAT-1 and AP-1 transcription factors.
[34-42]
Associated with a Th1 profile in C3HeB/FeJ and C57BL/6 mice: expression of
Th1-associated cytokines;
L. (L.) amazonensis Associated with the cleavage of MHC class II gene products in mice; [43-46]
Epitopes from CPB COOH-terminal extension modulate infection in BALB/c and
CBA mice: induce Th1 or Th2-related cytokines; stimulate CD8+ T lymphocytes;
Endogenous CP inhibitors are related with immune modulation
L. (L.) major Associated with a Th1 profile and reduction of IFN-γ expression in C3HeB/FeJ mice; [37]
L. (L.) pifanoi Reduces the percentage of infected murine macrophages when parasites are
treated with an anti-C-terminal extension antibody
[47]
L. (L.) chagasi Associated with Th1 profile in asymptomatic patients and IFN-γ production in cell
cultures;
[48]
Related to Th1 and Th2 profiles in cells from symptomatic human patients and
dogs: IFN-γ, IL-4 and IL-10 production in cell cultures;
CPC L. (L.) mexicana Contributes to resisting killing by macrophages [49-51]
L. (L.) chagasi Induces TGF-β expression in human cell culture [52]
Metallo-proteinases M8 Leishmania spp. Related to the hydrolysis and inactivation of immunoglobulin G; Inactivation of C3b
factor to complement C3bi; Adhesion and internalization in macrophages;
downregulation of gp63 expression induces Th1 profile in mice; cleave NF-κB
and prevent expression of IL-12 and iNOS in mice
[53-56]
L. (L.) major Associated with human NK cells proliferation and cleavage CD4 glycoprotein on
human T cells in culture.
[57,58]
L. (L.) mexicana In murine bone marrow macrophages, interferes with signaling cascades and affects
transcription factors by cleaving c-Jun, the central component of AP-1, alters signaling
through cleavage-activated protein tyrosine phosphatases in murine macrophages
[59]
Serine proteinases OPB L. (L.) donovani Allows parasites to infect the murine macrophage [60,61]
L. (L.) major Related to maintenance of murine macrophage infection [62]
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mammalian host [67,68].
A comparative genomic analysis carried out with the
different species of the genus Leishmania that have been
sequenced revealed that the number of proteinase genes
is kept constant among the various species. However,
there is a high diversity of proteinases in Leishmania, as
a survey of multiple databanks reveals that L. (V.) brazi-
liensis alone has at least forty-four cysteine proteinases,
twenty-three serine proteinases and ninety-seven metal-
loproteinase (http://tritrypdb.org, http://blast.ncbi.nlm.
nih.gov/). Therefore, due to the broad spectrum of ac-
tion of Leishmania proteinases while the parasite is in-
side the mammalian host, it is reasonable to propose a
correlation between proteinase activity and the clinical
manifestation of leishmaniasis.
Cysteine-proteinases from Leishmania as virulence factors
Many studies have identified cysteine proteinases (CPs)
as prevalent virulence factors in species that are classi-
fied under the Leishmania (Leishmania) mexicanacomplex, especially in the murine infection model used
for most of the CP studies. The efficacy of the use of CP
inhibitors for infection control can be interpreted as evi-
dence of the importance of these enzymes during the es-
tablishment of the infection in the host [69].
Cysteine proteases are enzymes that are known to play
critical roles in the pathogenesis of other parasitic proto-
zoa infections, as reviewed by [70], thus their import-
ance as virulence factors and their potential as drug
targets and vaccine candidates has been investigated ex-
tensively. The most studied CPs in Leishmania are
designated CPA, CPB and CPC, all of which are papain-
like and belong to the same group of CPs, clan CA, that
is divided into families, as follows: family C, including
cathepsin B-like (e.g., CPC) and cathepsin L-like (e.g.,
CPA and CPB) enzymes; family C2, including calpain-
like enzymes; and others [34,67,69-72].
Several CP genes have been characterized in Leish-
mania, mainly in species of the L. (L.) mexicana complex,
such as L. (L.) mexicana [73-75], Leishmania (Leishmania)
pifanoi [47,76] and Leishmania (Leishmania) amazonensis
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the cathepsin L-like cysteine proteinases gene cluster from
the Leishmania (Leishmania) donovani complex has been
previously described [79]. It has also been observed that
single nucleotide polymorphisms (SNPs) occurring in CPs,
which can vary according to the parasite’s life stage, could
be related to clinical characteristics such as a dermotropic
rather than a viscerotropic status [79].
Additionally, a high CP activity was observed in
extracts of L. (L.) amazonensis amastigotes, but promas-
tigotes from the exponential or stationary phases exhib-
ited very low proteolytic activity [77]. In this species of
Leishmania, a correlation between the levels of CP ex-
pression and virulence has been described [80]. In this
context, suppression of the CP genes diminished the
virulence of Leishmania (Leishmania) infantum in ham-
sters [81] and of Leishmania (Leishmania) chagasi in
human cell cultures [82].
CPs were also shown to play a key role in basic func-
tions and the interactions of Leishmania (Leishmania)
tropica with the host, as parasites treated with CP inhi-
bitors showed reduced viability, growth and pathogen-
icity [83]. In contrast, CPA was shown to be important
in the host-parasite interaction of L. (L.) infantum but
not to be essential for parasite replication [33].CPB as a major virulence factor in species of the L. (L.)
mexicana complex
Proof of the importance of CPBs as a major virulence
factor for species of the L. (L.) mexicana complex was
obtained in assays of experimental infections in BALB/c
mice using genetically modified parasites in which the
genes for CPA, CPB and CPC were deleted (Δcpa, Δcpb
and Δcpc strains). These assays showed that the absence
of CPA or CPC affected the parasites in a more discrete
fashion than the absence of CPB; parasites lacking CPB
had a greatly reduced ability to infect and induced fewer
lesions than the wild-type strain [34,35].
Other studies analyzed the effects of the reinsertion of
cpb genes in the Δcpb parasite strain; the reinsertion of a
single cpb gene did not fully restore parasite virulence,
but the reinsertion of multiple cpb genes (using a cos-
mid) was able to do so. These data suggest that the mul-
tiple copies of cpb genes present in the parasites genome
produce enzymes with complementary functions [36].
The role of CPB in the progression of infection in
distinct murine strains was variable. L. (L.) mexicana
remained able to continuously induce lesions in BALB/
c mice even after the depletion of the cpb genes, al-
though it did so at a much lower rate than wild strain
parasites, indicating that other virulence factors were
still effective. However, in the murine strains C3HeB/
FeJ and C57BL/6, the infection with mutant parasiteswas eventually controlled and the lesions were able to
heal [35-37].
Regarding the direct effect of CPB on the parasite’s
ability to control host responses, it was observed that
Δcpb L. (L.) mexicana parasites are unable to promote
IL-4 expression during an experimental infection of
BALB/c mice. The infected mice were thus able to
mount a Th1 response and limit lesion growth. After
multiple cpb genes were reinserted into the mutant para-
sites, the capacity to induce IL-4 production was
restored along with virulence [36].
It interesting to note that the subversion of immune
responses by a specific parasite species may present in
different manners depending on the mouse strain used.
For example, it has been reported that the virulence of
L. (L.) mexicana in the mouse strains C3HeB/FeJ and
C57BL/6 is not associated with the capacity to induce
IL-4 expression, as in BALB/c mice but is instead due to
the inhibition of the expression of Th1-associated cyto-
kines. Studies have shown that animals from these more
resistant strains were able to control lesion growth after
experimental infection with Δcpb parasites but were sus-
ceptible to wild strain parasites. In contrast, animals be-
came susceptible to infection by Δcpb parasites if the
IL12p40 or STAT4 genes were suppressed, suggesting
that wild-type parasites inhibit the expression of Th1-
related genes [37].
Additionally, experiments using cosmids to insert mul-
tiple L. (L.) mexicana cpb genes into L. (L.) major para-
sites have yielded similar results. After transfection with
the cpb-containing cosmids, L. (L.) major parasites
caused infections with higher parasitic loads and
reduced IFN-γ expression in C3HeB/FeJ mice than was
observed for infections with the wild-type L. (L.) major,
providing more evidence of the influence of CPB on the
expression of Th1-related genes [37].
The role of CPB from L. (L.) mexicana in the inhib-
ition of host IL-12 production was also analyzed in
macrophages and dendritic cells [38,39]. The role of
CPB in IL-12 inhibition was shown using assays with
Δcpb amastigotes that were less efficient at inhibiting
the lipopolysaccharide-related expression of IL-12 than
wild-type amastigotes. Supplementary evidence was
obtained from the observation that the use of CPB inhi-
bitors in wild-type parasites was similarly able to hinder
the ability of amastigotes to inhibit host IL-12 expression
[40]. The same study proposed a mechanism through
which CPB could inhibit IL-12 expression: the enzyme
could be involved in the cleavage of nuclear factor kappa
B (NF-κB) and its inhibitors (IκB α and β), thus prevent-
ing the expression of interleukins by the host. This IL-12
inhibition could not be observed in assays using Δcpb
amastigotes or promastigotes, because unlike amasti-
gotes, promastigotes only express low levels of CPB [40].
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tivity of other transcriptional factors was further ana-
lyzed in another study that showed that this proteinase
affects other transcription factors, such as STAT-1 and
AP-1, as well as NF-κB, by impeding their translocation
to the nucleus and thus impairing the production of NO
that is induced by IFN-γ [41]. Differences in the way
that promastigotes and amastigotes modulate NF-κB ac-
tivity were also observed: while the former cleaves the
p65 subunit to a smaller p35 subunit, the latter com-
pletely degrades the p65 subunit.
Another effect of CPB on the balance of Th responses
occurs through the cleavage of MHC proteins. There is
evidence that L. (L.) amazonensis CPB is able to cleave
MHC class II proteins inside the parasitophorous vacu-
ole of colonized host cells. Consequently, the host im-
mune response could be partially inhibited or,
alternatively, be mediated by other immune components
such as the MHC class I gene products [43].
The effects of CPB on the murine host immune sys-
tem has also been tested by subcutaneously injecting an
enzymatically active recombinant CPB protein into the
hind paw of BALB/c mice. Even without any actual para-
sites infecting the mice, there was an increase in IL-4
and IL-5 expression (Th2-related cytokines) and in the
levels of circulating IgE. These effects may be partially
explained by the ability of CPB to cleave CD23 (low
affinity IgE receptor) and CD25 (IL-2 receptor), as a
similar assay using an inactive recombinant CPB had
no such effects on the murine hosts [42].
Importance of CPB as a virulence factor in species from
other complexes
In spite of the substantial advances in knowledge about
CPs from the L. (L.) mexicana complex and, to a lesser
degree, of the L. (L.) donovani complex, less is known
about CPs from L. (V.) braziliensis, the most important
etiological agent of the mucocutaneous form of the dis-
ease in the New World. Within this context, our group
has been working in an attempt to clarify the biological
role of these enzymes. In a recent study, we were able to
identify the cellular localization of CPs and their mech-
anism of anchoring to the parasite plasma membrane
[84]. The organization of the cpb genes was also deter-
mined for this parasite species, along with the subsites
of specificity for the recombinant CPB [85].
Most studies about CPB’s activity as an immunomodu-
lator were based on the murine model using species
from the L. (L.) mexicana complex; however, an in vitro
study using cells cultured from dogs and human patients
proved that a recombinant CPB from L. (L.) chagasi
(rLdccys1) is able to induce cytokine production even
in these distinct models. It was shown that rLdccys1
can induce IFN-γ production in cell cultures fromasymptomatic patients, IFN-γ, IL-4 and IL-10 in oligo-
symptomatic patients and IL-4 and IL-10 (at lower
levels) in symptomatic patients and dogs [48].
Immunological effects of the COOH-terminal extension of
CPB
In addition to the aforementioned influence of the pro-
teolytic activity of CPB on the host immune system, the
COOH-terminal extension (CTE) of CPB has also been
reported to influence the interaction of parasites with
the host immune system. The CTE is hydrolyzed when
CPB is processed to its mature form [86] and is secreted
into the extracellular environment [78]. Because the
CTE has also been observed inside host cells [65], this
polypeptide may interact with and alter the host immune
system.
A synthetic peptide based on the CTE of L. (L.) ama-
zonensis (PI) was shown to induce the expression of
Th2-related cytokines in cells cultured from BALB/c
mice, whereas cells from CBA mice exposed to the same
peptide expressed cytokines related to both Th1 and
Th2 responses. T cell proliferation was also stimulated
by the synthetic peptide, especially that of CD8+ T cells.
Additionally, when used for in vivo assays with infected
mice, PI caused increased growth of lesions for BALB/c
mice but not for CBA mice [44]. Our group recently
conducted a study using in silico simulations of the
interactions between MHC and CTE-derived epitopes,
and the results suggested that these interactions could
be related to the production of specific cytokines [45].
The CTE may also play a role in macrophage infec-
tions with L (L.) pifanoi or L. (L.) amazonensis, as incu-
bation of parasites with anti-CTE antibodies prior to
their interaction with macrophages led to a reduction in
the number of infected cells. This effect was more dra-
matic with amastigotes than with promastigotes, and
pre-incubation of the parasites with an antibody specific
to the L. (L.) pifanoi CPB catalytic domain had no effect
in macrophage infection [47].
Non-CPB cysteine proteinases
Regarding the importance of other non-CPB CPs, stud-
ies indicate that CPC also plays a relevant role as a
Leishmania virulence factor; although amastigotes from
a Δcpc L. (L.) mexicana strain were still able to infect
macrophages in vitro at rates comparable to the wild-
type strain [49], these mutant parasites were more sus-
ceptible to killing by host cells [50,51]. Additionally,
there is evidence that CPC may contribute to some of
the immunoregulatory activities of L. (L.) chagasi, such
as the parasite’s capacity to induce TGF-β expression in
human cell cultures [52].
Regarding CPA, assays based on gene suppression
showed that a CPA (cys1) from L. (L.) infantum acts as a
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less infective for mammalian hosts and for cells in vitro
[33].
The synergy between the activities of the CPs that con-
tribute to L. (L.) mexicana virulence was verified in assays
using parasites that had a combination of CP genes sup-
pressed (Δcpa/ Δcpb). These mutants were even less in-
fective in BALB/c mice than other strains with just one
type of CP gene suppressed, indicating the complemen-
tary activity of these enzymes [34]. A reduction in the
virulence of L. (L.) mexicana after CP gene suppression
was also observed in infection assays in hamsters and in a
human mononuclear phagocytic system [87].
An interesting biological function related to the CPA
gene has been described. Double =Δcpa/cpb mutants of
L. (L.) mexicana have a disrupted autophagy pathway
and are also unable to undergo metacyclogenesis and
transformation to amastigotes [77]. CPA and CPB are
two major lysosomal cysteine peptidases that may func-
tion similarly to the aspartic peptidase PEP4 and the
serine peptidase PRB1 in Saccharomyces cerevisiae.
Autophagy is believed to be necessary to the process of
cell differentiation [88].
Endogenous Inhibitors of CPs
The role of the endogenous CP inhibitors expressed by
Leishmania (ICPs) in immune modulation has also been
studied. The L. (L.) mexicana mutants that overex-
pressed the ICPs led to decreased antibody and IL-4
production but induced the production of increased
levels of IFN-γ in murine hosts when compared to a
wild-type strain [46]. These observations reinforce the
important role of CPs as immune modulation tools, es-
pecially in species of the L. (L.) mexicana complex.
Metalloproteinases of Leishmania as virulence factors
The major surface protein (MSP or gp63) is a metallo-
proteinase (MP) that belongs to the metzincin class
(peptidase family M8) and is abundantly expressed on
the surface of Leishmania spp. and other related trypa-
nosomatid protozoans [89-92]. Its biological activity is
associated with protecting the parasites against the ac-
tion of host enzymes in the midgut of insect vectors and
the phagolysosomes of macrophages. Additionally, gp63
is required for the resistance of promastigotes to
complement-mediated lysis in the mammalian host, as
the presence of an enzymatically active form of this pro-
teinase greatly reduced the fixation of the terminal com-
plement components on parasites and increased the
conversion of C3b to the inactive form C3bi [53,54]. The
cellular localization of metalloproteinases with domains
homologous to gp63 was investigated in L. (V.) brazi-
liensis and showed that these enzymes are mainly
located in the flagellar pocket of the parasite [93].Studies of the direct effects of metalloproteinases on the
immune system of mammalian hosts show that gp63 is
important during macrophage infection and modulates
the cytokine immune response, as downregulation of
gp63 expression in parasites rendered them more sus-
ceptible to complement-mediated lysis and led to the de-
velopment of a Th1-type response at the site of
inoculation and its draining lymph node [55].
Natural killer (NK) cells are another type of immune
cell that have been shown to be affected by Leishmania
gp63. The ability of promastigotes to suppress this cell
type is dependent on gp63 expression, as a L. (L.) major
gp63 mutant strain loses its ability to hinder the prolif-
eration of NK cells and to inhibit the expression of sur-
face receptors on these cells [57].
Gp63 has also been shown to interfere with signaling
cascades and to affect transcription factors, thus pre-
venting host cells from adequately responding to the
parasites during infection. One example of such activity
is the gp63-dependent cleavage of c-Jun, the central
component of the transcriptional complex AP-1, by L.
(L.) mexicana parasites. Interestingly, gp63 retrieved
from culture supernatants maintains the capacity to
cleave c-Jun, suggesting that when secreted by the para-
sites, this enzyme may use a phagocytosis-independent
mechanism to enter host cells [59].
An alternative immune modulation effect of gp63
occurs by the activation of protein tyrosine phosphatases
(PTPs) in macrophages, leading to decreased NO pro-
duction and attenuated innate inflammatory responses,
therefore increasing the parasite’s odds of survival. It
was reported that gp63 activates at least three macro-
phage PTPs through its proteolytic activity and that this
process is partially dependent on a lipid raft-based
mechanism [94].
Similar to CPB, g63 has also been implicated in the
cleavage of NF-κB, but this activity has a more subtle
and specific purpose than simply preventing the tran-
scriptional factor from reaching the nucleus. Instead,
gp63 cleaves the NF-κB subunit p65 into a smaller sub-
unit (p35) that enters the nucleus of the host cell and
triggers the expression of chemokines. By subverting the
proper function of the transcriptional machinery, the
parasites are able to recruit phagocytic cells to serve as
hosts while preventing the expression of host factors as
IL-12 and iNOS that threaten their survival, [56]. The
gp63 from L. (L.) major and L. (L.) donovani can also
cleave CD4 glycoprotein on human T cells in culture, re-
vealing yet another example of the influence that Leish-
mania parasites have on the host immune system. The
cleavage was measured by assessing the binding of spe-
cific antibodies binding CD4 glycoprotein on the surface
of cells, and this effect was detected using both promas-
tigotes and purified gp63 on the cell cultures [58].
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Serine proteinases (SPs) have also been shown to act as
virulence factors and influence host immune responses
during Leishmania infection, but, unlike CPB for
cysteine-proteinases and gp63 for metalloproteinases,
there is not yet a specific SP that has been shown to be
responsible for these effects. Reports indicate that the
levels of surface SPs diminishes in attenuated strains of
L (L.) donovani and that a 115 kDa SP seems to be
related to the parasite’s ability to infect the host [95].
A SP of Leishmania, oligopeptidase B (OPB; Clan SC,
family S9A oligopeptidase B), was identified and charac-
terized by mass spectrometry and gene deletion [60]. It
was suggested that during differentiation to the amasti-
gote form, OPB is upregulated and participates in the
covering of parasite surface with enolase and plasmino-
gen. The amastigotes are then able to replicate un-
detected within the macrophage.
The direct effects of OPB on the host immune system
was demonstrated by examining the effect of infection
with an OPB mutant strain on the expression of host
genes. Infection of macrophages in culture with a wild-
type L. (L.) donovani strain results in changes in the ex-
pression of 23 genes, but infection of these same cells
with a mutant strain in which the oligopeptidase B gene
was deleted leads to changes in 495 genes, an increase of
approximately 21x in the number of genes affected by
the infection. This suggests a relationship between oligo-
peptidase B expression and the ability of Leishmania to
remain undetected in macrophage infections [60]. OPB-
deficient L. (L.) major mutants were recently shown to
be able to grow normally as promastigotes even though
they are slightly deficient in their ability to undergo dif-
ferentiation to metacyclic promastigotes, but they were
significantly less able to infect and survive within macro-
phages in vitro despite maintaining their virulence in
mice. These data suggest that L. (L.) major OPB itself is
not a prevalent virulence factor but rather acts in con-
junction with other factors, indicating functional differ-
ences between trypanosomes and Leishmania in their
interaction with the mammalian host [96].
Another class of SP, the subtilisin protease (SUB; Clan
SB, family S8) of L. (L.) donovani, was cloned and shown
to possess a unique catalytic triad. When this SP gene
was deleted, the ability of the parasite to undergo pro-
mastigote to amastigote differentiation in vitro was
reduced. Furthermore, the activity of this Leishmania SP
is increased by several fold in amastigotes when com-
pared to promastigotes, suggesting an important role for
this enzyme in the vertebrate-inhabiting stages of the
parasite [61].
Additional evidence of immune modulation by SPs
was obtained by the observation that immunization with
a soluble proteases fraction isolated from a mixture of L.(L.) amazonensis antigens increased the susceptibility of
mice to a subsequent experimental infection. This effect
was eliminated by treating the protease fraction with SP
inhibitors but not with CP inhibitors [62].
Importance of proteinases from mammalian host in the
progression of the infection
Although the proteinases from parasites play important
roles in immunomodulating the host response and, con-
sequently, the outcome of the infection, proteinases
from the host also affect the dynamics of the infection
and the development of the lesion. For example, matrix
metalloprotease-9 (MMP-9) interferes with the re-
epithelization of chronic wounds in humans. In situa-
tions where the inflammation continues for a long
period, TNF-α and, subsequently, MMP-9 persist,
thereby preventing the migrating keratinocytes from
forming new attachments to a newly synthesized base-
ment membrane. This suggests a mechanism whereby
the presence of high levels of MMP-9 delays the process
of normal wound healing [97].
These data are correlated with findings that associate a
high number of cells producing IFN-γ, IL-10 and TNF-
α, in addition to elevated levels of MMP-9 activity in
lesions, with a poor response to therapeutics for cutane-
ous leishmaniasis (CL) [98]. Indeed, infection with L. (L.)
chagasi stimulates murine macrophages to produce
MMP-9 [99]. Conversely, elevated levels of MMP-2
mRNA were detected in lesions from patients with good
responses to treatment [98], an observation consistent
with other reports that showed that increased MMP-2
levels were required for cutaneous wound re-
epithelization [100]. Interleukin-10 is observed at higher
levels in patients with good immune responses [98] and
seems to be unique among the cytokines in its ability to
suppress the production and activation of MMPs, thus
having an important matrix-protective role during in-
flammation [101].
Remarks
The network of interactions that take place during the
evolution of the Leishmania infection in the mammal
host is highly complex and involves a series of responses
and counter-responses from both organisms. In this con-
text, proteinases appear as factors of pivotal importance,
playing central roles in many of the interactions between
parasite and host (Table 1).
Although most of the literature currently available on
this subject is focused on cysteine-, metallo- and serine-
proteinases from Leishmania species, the importance of
host proteinases, such as matrix metalloproteinases, and
their role in the subversion of host’s immune responses
by the parasites must not be overlooked, as some reports
already point to their direct contribution to determining
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to analyze the participation of aspartyl-proteinases from
Leishmania species, as their expression changes between
morphological forms and may therefore be related to the
responses necessary to survive in distinct micro-
environments [65]. Therefore, to fully understand how
the Leishmania infection progresses and to be able to
find suitable targets for drug development and options
for patient treatment, it is important to consider the in-
fluence of proteinases from host and parasite alike, as
disregarding one in favor of the other may lead to incor-
rect conclusions and inadequate, if not harmful, treat-
ment of the disease.
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